![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
On 16 May 2018, Lonza is hosting a free 60-minute webinar on innovative technologies for building advanced human liver culture platforms that better mimic common liver diseases, such as non-alcoholic fatty liver disease, liver fibrosis and hepatitis B viral infection.
The webinar will offer valuable insights into primary human hepatocytes and other liver cell types, such as hepatic stellate cells, and how they can be used to create more physiologically relevant human liver culture models. The benefits of using long-term cell characterization and drug validation data will also be discussed. The webinar will conclude with an outlook on emerging trends that could reshape liver disease research and drug discovery to the benefit of patients worldwide.
During the webinar Dr. Salman Khetani, renowned researcher from the Department of Bioengineering at the University of Illinois, Chicago (USA), will explore:
- Drug discovery related to liver diseases
- Methods for building advanced liver models
- Emerging trends in liver disease research
Anyone interested in attending the webinar can register here.
Date: Wednesday, 16 May 2018
8 AM PDT (Los Angeles)
10 AM CDT (Chicago)
4 PM BST (London)
5 PM CEST (Berlin)
Further information can be found on the Hepatocytes/ADMETox product page. All webinar registrants will receive a link once the recording is available to view “on demand” via the Lonza website.
More information about Lonza’s upcoming webinars is available here: www.lonza.com/webinars.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com
About Lonza Group Ltd
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
